vs
Esperion Therapeutics, Inc.（ESPR）与Live Oak Bancshares, Inc.（LOB）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Live Oak Bancshares, Inc.的1.2倍（$168.4M vs $145.5M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 18.4%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 7.7%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Live Oak Bancshares, Inc.是一家美国金融控股公司，旗下子公司Live Oak Bank总部位于北卡罗来纳州威尔明顿，业务覆盖美国全部50个州，专注为小企业主提供金融服务，2022年按放贷金额计是美国SBA 7(a)贷款项目的头部放贷机构。
ESPR vs LOB — 直观对比
营收规模更大
ESPR
是对方的1.2倍
$145.5M
营收增速更快
ESPR
高出125.4%
18.4%
两年增速更快
ESPR
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $145.5M |
| 净利润 | — | $27.9M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | 19.2% |
| 营收同比 | 143.7% | 18.4% |
| 净利润同比 | — | 187.6% |
| 每股收益（稀释后） | $0.32 | $0.60 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRLOB
| Q1 26 | — | $145.5M | ||
| Q4 25 | $168.4M | $161.9M | ||
| Q3 25 | $87.3M | $146.1M | ||
| Q2 25 | $82.4M | $143.7M | ||
| Q1 25 | $65.0M | $126.1M | ||
| Q4 24 | $69.1M | $116.9M | ||
| Q3 24 | $51.6M | $129.9M | ||
| Q2 24 | $73.8M | $125.5M |
净利润ESPRLOB
| Q1 26 | — | $27.9M | ||
| Q4 25 | — | $46.2M | ||
| Q3 25 | $-31.3M | $26.5M | ||
| Q2 25 | $-12.7M | $23.4M | ||
| Q1 25 | $-40.5M | $9.7M | ||
| Q4 24 | — | $9.9M | ||
| Q3 24 | $-29.5M | $13.0M | ||
| Q2 24 | $-61.9M | $27.0M |
营业利润率ESPRLOB
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 38.2% | ||
| Q3 25 | -11.4% | 25.0% | ||
| Q2 25 | 8.6% | 21.7% | ||
| Q1 25 | -34.0% | 10.4% | ||
| Q4 24 | -6.4% | 11.3% | ||
| Q3 24 | -31.0% | 13.7% | ||
| Q2 24 | 3.5% | 28.7% |
净利率ESPRLOB
| Q1 26 | — | 19.2% | ||
| Q4 25 | — | 28.5% | ||
| Q3 25 | -35.9% | 18.1% | ||
| Q2 25 | -15.4% | 16.3% | ||
| Q1 25 | -62.2% | 7.7% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | -57.2% | 10.0% | ||
| Q2 24 | -83.9% | 21.5% |
每股收益（稀释后）ESPRLOB
| Q1 26 | — | $0.60 | ||
| Q4 25 | $0.32 | $0.96 | ||
| Q3 25 | $-0.16 | $0.55 | ||
| Q2 25 | $-0.06 | $0.51 | ||
| Q1 25 | $-0.21 | $0.21 | ||
| Q4 24 | $-0.14 | $0.22 | ||
| Q3 24 | $-0.15 | $0.28 | ||
| Q2 24 | $-0.33 | $0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $1.3B |
| 总资产 | $465.9M | $15.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRLOB
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
股东权益ESPRLOB
| Q1 26 | — | $1.3B | ||
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.2B | ||
| Q2 25 | $-433.5M | $1.1B | ||
| Q1 25 | $-426.2M | $1.0B | ||
| Q4 24 | $-388.7M | $999.0M | ||
| Q3 24 | $-370.2M | $1.0B | ||
| Q2 24 | $-344.2M | $961.0M |
总资产ESPRLOB
| Q1 26 | — | $15.3B | ||
| Q4 25 | $465.9M | $15.1B | ||
| Q3 25 | $364.0M | $14.7B | ||
| Q2 25 | $347.1M | $13.8B | ||
| Q1 25 | $324.0M | $13.6B | ||
| Q4 24 | $343.8M | $12.9B | ||
| Q3 24 | $314.1M | $12.6B | ||
| Q2 24 | $352.3M | $11.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRLOB
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $158.2M | ||
| Q3 25 | $-4.3M | $62.3M | ||
| Q2 25 | $-31.4M | $49.2M | ||
| Q1 25 | $-22.6M | $-33.0M | ||
| Q4 24 | $-35.0M | $156.8M | ||
| Q3 24 | $-35.3M | $47.4M | ||
| Q2 24 | $-7.2M | $29.5M |
自由现金流ESPRLOB
| Q1 26 | — | — | ||
| Q4 25 | — | $143.5M | ||
| Q3 25 | — | $60.6M | ||
| Q2 25 | — | $47.8M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | $107.5M | ||
| Q3 24 | $-35.5M | $41.0M | ||
| Q2 24 | $-7.3M | $12.3M |
自由现金流率ESPRLOB
| Q1 26 | — | — | ||
| Q4 25 | — | 88.6% | ||
| Q3 25 | — | 41.4% | ||
| Q2 25 | — | 33.3% | ||
| Q1 25 | — | -28.0% | ||
| Q4 24 | — | 91.9% | ||
| Q3 24 | -68.7% | 31.6% | ||
| Q2 24 | -9.9% | 9.8% |
资本支出强度ESPRLOB
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 9.1% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 1.8% | ||
| Q4 24 | 0.0% | 42.2% | ||
| Q3 24 | 0.3% | 4.9% | ||
| Q2 24 | 0.1% | 13.7% |
现金转化率ESPRLOB
| Q1 26 | — | — | ||
| Q4 25 | — | 3.42× | ||
| Q3 25 | — | 2.35× | ||
| Q2 25 | — | 2.10× | ||
| Q1 25 | — | -3.39× | ||
| Q4 24 | — | 15.84× | ||
| Q3 24 | — | 3.64× | ||
| Q2 24 | — | 1.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
LOB
暂无分部数据
